The iiiiiimmune system is the body’s main form of defense. Cancer is often elusive and in some patients, like solid tumors such as melanoma, where the body’s immune system does not detect the cancer and therefore does not develop the proper response to fight. We are conducting clinical trials with an investigational toll-like receptor agonist, tilsotolimod for intratumoral injection in order to turn on the immune response. Intratumoral injections appear to very selectively activate cancer-fighting cells (T- cells) within tumors that the body’s immune system is not recognizing. This may alter the tumor microenvironment thereby, enabling, or empowering additional therapies such as checkpoint inhibitors to have a more potent and sustainable effect against the tumors.
Oncology targets are currently being assessed for our third-generation antisense technology, which uses gene silencing oligonucleotides (GSOs). We believe that, based on its validation in pre-clinical models, our antisense technology has the potential to overcome the remaining hurdles of current antisense technologies, including efficient delivery without a carrier, reduced immunotoxicity, and increased potency.